MedTrace Logo

Aerobic Exercises on Persisted Post Burn Anemia

NCT06849479 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2025-02-27

No results posted yet for this study

Summary

Fourty patients who have total body surface area ranged from 20% to 35% of burn, anemic and 8th to 16th week post burn will participate in this study, the patients will be randomly divided into two equal groups (20 patients for each group): Group A (Experimental Group) (Aerobic exercise and medical treatment):

Group B ( Control Group) (Medical treatment group):

Conditions

  • Burns

Interventions

PROCEDURE

Aerobic exercise and medical treatment

Aerobic exercise training was done for 30 minutes, day after day (3 sessions weekly) for 6 weeks. Each session started by warming up phase that was walking on treadmill for 5 minutes at 20% of target heart rate. Active phase after warming up was walking on treadmill for 20 min at 50-70 % of target heart rate. And cooling down phase after the active phase of exercise was walking on treadmill for 5 minutes at 20 % of the target heart rate

DIETARY_SUPPLEMENT

Medical treatment group

patient received supplement in the form of one capsule daily, that contain iron supplement (10 mg) and multi vitamins (B1=0.6 mg;, B2=0.6 mg; B6=0.6 mg; B12= 1.2 mc and C=30 mg) as well as essential trace elements (Zinc=5 mg; Copper=0.44 mg; Folic acid=200 mc and Biotin=12 mc

Sponsors & Collaborators

  • Cairo University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-01
Primary Completion
2025-03-31
Completion
2025-03-31

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06849479 on ClinicalTrials.gov